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ARTICLE
JunB regulates homeostasis and suppressive
functions of effector regulatory T cells
Shin-ichi Koizumi1, Daiki Sasaki1, Tsung-Han Hsieh 1, Naoyuki Taira1, Nana Arakaki2, Shinichi Yamasaki2,
Ke Wang1, Shukla Sarkar1, Hiroki Shirahata1, Mio Miyagi1 & Hiroki Ishikawa1
Foxp3-expressing CD4+ regulatory T (Treg) cells need to differentiate into effector Treg
(eTreg) cells to maintain immune homeostasis. T-cell receptor (TCR)-dependent induction of
the transcription factor IRF4 is essential for eTreg differentiation, but how IRF4 activity is
regulated in Treg cells is still unclear. Here we show that the AP-1 transcription factor, JunB,
is expressed in eTreg cells and promotes an IRF4-dependent transcription program. Mice
lacking JunB in Treg cells develop multi-organ autoimmunity, concomitant with aberrant
activation of T helper cells. JunB promotes expression of Treg effector molecules, such as
ICOS and CTLA4, in BATF-dependent and BATF-independent manners, and is also required
for homeostasis and suppressive functions of eTreg. Mechanistically, JunB facilitates the
accumulation of IRF4 at a subset of IRF4 target sites, including those located near Icos and
Ctla4. Thus, JunB is a critical regulator of IRF4-dependent Treg effector programs, high-
lighting important functions for AP-1 in Treg-mediated immune homeostasis.
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Regulatory T (Treg) cells can suppress a variety of immuneresponses and contribute to immune homeostasis1,2. Theyrequire the lineage-specifying transcription factor, forkhead
box P3 (Foxp3), for development, maintenance of cell identity,
and suppressive functions3–5. Thymic Treg (tTreg) cells develop
in the thymus and then circulate through blood and lymphoid
tissues as central Treg (cTreg) cells, displaying a CD62Lhigh (hi)
phenotype6. While circulating in the periphery, some cTreg cells
differentiate into effector Treg (eTreg) cells, exhibiting an acti-
vated cell phenotype (CD62Llow (lo)), depending on T-cell
receptor (TCR) stimuli7. cTreg and eTreg cells express various
genes differentially and perform non-redundant functions6,8–13.
For example, cTreg cells express lymph node-homing receptors
CD62L and CC chemokine receptor 7 (CCR7), whereas eTreg
cells preferentially express other chemokine receptors and accu-
mulate in non-lymphoid tissues14,15. In addition, eTreg cells
express higher levels of Treg effector molecules, such as inducible
T-cell costimulator (ICOS) and cytotoxic T-cell-associated anti-
gen 4 (CTLA4), than do cTreg cells, which are likely important
for eTreg-suppressive functions and homeostasis7,14,16–18. Fur-
thermore, eTreg cells can express transcription factors, T-box
transcription factor (T-bet), GATA-binding protein 3 (GATA3),
and retinoic acid receptor-related orphan receptor (ROR)γt,
which are associated with roles unique to eTreg cells, to regulate
functions of distinct T helper cells19–24.
To activate the effector program, Treg cells require TCR-
dependent transcriptional regulatory mechanisms that
CD4+Foxp3− conventional T (Tconv) cells also use for
differentiation12,25–27. For example, the transcription factor,
interferon regulatory factor 4 (IRF4), which promotes differ-
entiation of several types of T helper cells and cytotoxic CD8+
T cells28–32, is induced in Treg cells upon TCR stimulation and
participates in eTreg differentiation7,33. Treg-speciﬁc Irf4-deﬁ-
cient mice develop multi-organ autoimmunity, exhibiting pro-
found Th2 responses34. Furthermore, basic leucine zipper
transcription factor ATF-like (BATF), one of the AP-1 family of
transcription factors, which is also essential for differentiation of
Th17 cells and cytotoxic CD8+ T cells35,36, is highly expressed in
eTreg cells, and Batf-deﬁcient Treg cells cannot suppress T-cell-
mediated colitis24. BATF and IRF4 bind to AP-1-IRF-composite
element (AICE) motifs37–40, but how BATF and other AP-1
transcription factors regulate IRF4 activity in the eTreg tran-
scriptional program is not fully understood.
JunB is another member of the AP-1 family of transcription
factors37. AP-1 factors contain basic leucine zipper (bZIP)
domains, by which they form homodimers or heterodimers with
other AP-1 or bZIP-containing transcription factors41. JunB can
dimerize with BATF in a variety of cells, including CD8+ T cells
and Th17 cells37. We and other groups recently reported that
JunB regulates the BATF- and IRF4-dependent Th17 cell tran-
scriptional program that is critical for pathogenic functions of
Th17 cells42–45. JunB promotes DNA-binding of BATF and IRF4
at IRF4 target sites, including those associated with Th17-related
genes, Rorc and Il23 receptor (Il23r), during Th17
differentiation42,43. However, functions of JunB in Treg cells
remain unclear.
Here, we show that JunB is expressed in eTreg cells, and is
required for eTreg-mediated immune homeostasis. Treg-speciﬁc
deletion of JunB induces severe inﬂammation in lung and colon.
JunB facilitates expression of ICOS and CTLA4 in BATF-
dependent and -independent fashions, and is pivotal for home-
ostasis and suppressive functions of eTreg cells. Mechanistically,
JunB is required for DNA-binding of IRF4 at IRF4 target sites
associated with Icos and Ctla4. Thus, we show crucial
functions for JunB in the IRF4-dependent eTreg transcriptional
program.
Results
JunB expression in Treg cells. To understand JunB functions in
Treg cells, we ﬁrst analyzed expression of JunB in murine Treg
cells by ﬂow cytometry. In spleen, a subset of Foxp3+ Treg cells,
but not Foxp3− Tconv cells, expressed substantial levels of JunB
(Fig. 1a and Supplementary Fig. 1a). Moreover, in lung, Treg cells,
as well as Tconv cells, uniformly expressed high levels of JunB,
and the expression level of JunB in Treg cells was signiﬁcantly
higher than in Tconv cells (Fig. 1b). We next assessed whether
there is a correlation between JunB expression and distinct Treg
subpopulations. cTreg cells circulate through secondary lymphoid
organs, whereas eTreg cells preferentially accumulate in periph-
eral tissues6,14,24. We analyzed JunB expression in CD62LhiC-
D44lo cTreg cells and CD62Llo eTreg cells (Supplementary
Fig. 1b). Consistent with enrichment of JunB-expressing Treg
cells in the lung, we found that JunB was expressed in eTreg cells,
but not in cTreg cells in spleen (Fig. 1c). eTreg cells hetero-
geneously express surface molecules such as ICOS, T-cell
immunoreceptor with Ig and ITIM domains (TIGIT), and killer
cell lectin-like receptor 1 (KLRG1)11,18,24,46–49. We noted that
JunB expression was correlated with expression of ICOS, TIGIT,
and KLRG1 (Fig. 1d and Supplementary Fig. 1c, d). As reported
previously, IRF4 and BATF24,33,34, which are required for eTreg
differentiation, were also expressed at elevated levels in ICOS-
expressing eTreg cells (Supplementary Fig. 1e, f). JunB expression
can be regulated transcriptionally and post-transcriptionally in
various signaling pathways50,51. To determine whether induction
of JunB is transcriptionally regulated in eTreg cells, we sorted
cTreg and eTreg cells by ﬂuorescence-activated cell sorting
(FACS) and analyzed expression of mRNA for Junb, as well as
Batf and Irf4, by reverse transcriptase quantitative polymerase
chain reaction (RT-qPCR) analysis. Although mRNA expression
of Batf and Irf4 was upregulated in eTreg cells, there was no
difference of Junb mRNA expression between cTreg and eTreg
cells (Fig. 1e), suggesting that, unlike BATF and IRF4, JunB
expression is regulated post-transcriptionally in eTreg cells. These
data indicate that JunB is expressed in a subset of eTreg cells.
To investigate how JunB expression is regulated in Treg cells,
we examined expression of JunB, as well as of BATF and IRF4, in
TCR-stimulated Treg cells, because TCR signaling is necessary for
differentiation of eTreg cells7,52. We isolated CD4+CD25+ Treg
cells from spleens and conﬁrmed that > 95% of the cells expressed
Foxp3 (Supplementary Fig. 1g). We activated Treg cells with anti-
CD3 and anti-CD28 antibodies in the presence of interleukin (IL)
−2. Flow cytometry analysis showed that expression of JunB and
BATF was induced by both anti-CD28 antibody and IL-2
stimulation in an additive manner, compared with expression
levels in Treg cells stimulated with anti-CD3 antibody alone
(Fig. 1f). On the other hand, IRF4 expression was markedly
induced by stimulation with anti-CD3 antibody alone, and it was
further enhanced by either anti-CD28 antibody or IL-2 stimula-
tion (Fig. 1f). However, the additive effect of anti-CD28 antibody
and IL-2 stimulation was not observed in IRF4 expression
(Fig. 1f). In summary, these results suggest that dynamic
expression of JunB in TCR-stimulated Treg cells might regulate
generation and/or function of eTreg cells.
Treg-speciﬁc deletion of JunB induces autoimmunity. To
investigate physiological functions of JunB in Treg cells, we
crossed mice harboring loxp-ﬂanked Junb alleles (Junbﬂ/ﬂ) with
mice harboring Foxp3 promoter-driven cre recombinase
(Foxp3Cre). This generated Treg-speciﬁc, Junb-deﬁcient (Foxp3-
CreJunbﬂ/ﬂ) mice (Supplementary Fig. 2a). Flow cytometry ana-
lysis conﬁrmed efﬁcient deletion of JunB in CD4+Foxp3− Treg
cells in Foxp3CreJunbﬂ/ﬂ mice (Supplementary Fig. 2a). In
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contrast, substantial numbers of CD4+Foxp3− Tconv cells
and CD8+ T cells expressed JunB in the lung and colon of
Foxp3CreJunbﬂ/ﬂ mice (Supplementary Fig. 2a), albeit at a lower
number compared with control mice, probably owing to leaky
expression of Cre in these cells53. Foxp3CreJunbﬂ/ﬂ mice were
born at normal mendelian ratios, but they were markedly smaller,
and by 4 weeks of age their weights were already signiﬁcantly
lower than those of control mice (Fig. 2a and Supplementary
Fig. 2b). About 60% of Foxp3CreJunbﬂ/ﬂ mice died within
6 months (Fig. 2b). We observed signiﬁcant increases in size and
cellularity of cervical lymph nodes, but not other lymph nodes
and spleens in Foxp3CreJunbﬂ/ﬂ mice, compared with Foxp3Cre-
Junb+/+ mice (Fig. 2c and Supplementary Fig. 2c). In histo-
pathological analysis, Foxp3CreJunbﬂ/ﬂ mice exhibited higher
inﬂammation scores in lung and colon (but not in liver or skin),
than did control mice (Fig. 2d).
In Foxp3CreJunbﬂ/ﬂ mice, although increased cellularity
was restricted to cervical lymph nodes (Fig. 2c), frequencies of
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Fig. 1 Expression of JunB is upregulated in eTreg cells. a–d Flow cytometry analysis of JunB in Foxp3+ (Treg) or Foxp3− (Tconv) cells isolated from spleen a
and lung b, Treg cells bearing CD62LhiCD44lo phenotypes (cTreg) or CD62Llo phenotypes (eTreg) c, and ICOS+ or ICOS− eTreg cells d isolated from
spleen of wild-type C57BL/6 mice (7–10-week-old). Cd4creJunbﬂ/ﬂ mice were used as negative controls. e CD62LhiCD44lo cTreg and CD62Llo eTreg cells
were sorted by FACS, and Junb mRNA expression was analyzed by qRT-PCR. a–e Error bars indicate s.d. (n= 4). *P < 0.05; N.S., not signiﬁcant (unpaired
two-tailed Student’s t test). MFI, mean ﬂuorescence intensity. f JunB expression was analyzed by ﬂow cytometry in CD4+CD25+ Treg cells activated with
indicated stimuli for 72 h. Error bars indicate s.d. (n= 3). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). Data represent two
independent experiments
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CD4+Foxp3− Tconv cells exhibiting the activated cell phenotype
(CD62LloCD44hi) were markedly more abundant than in Foxp3-
CreJunb+/+ mice in all secondary lymphoid tissues analyzed and in
lung (Fig. 2e, Supplementary Fig. 2d). Total B cells (B220+CD19+),
germinal center B cells (B220+CD19+GL-7+Fas+), and plasma
cells (CD138+B220−) were also signiﬁcantly increased in the
cervical lymph nodes, but not in the spleen or Peyer’s patches, in
Foxp3CreJunbﬂ/ﬂ mice, compared with Foxp3CreJunb+/+ mice
(Supplementary Fig. 3a–c). Furthermore, mass cytometry analysis
revealed increased frequencies of granulocytes with unaltered
JunB expression levels in these cells in spleens of Foxp3CreJunbﬂ/ﬂ
mice (Fig. 2f), indicating that JunB in Treg cells is important for
maintenance of leukocyte homeostasis. We also analyzed levels of
serum immunoglobulins by enzyme-linked immunosorbent assay
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(ELISA) and found that Foxp3CreJunbﬂ/ﬂ mice produced
signiﬁcantly elevated levels of serum IgG1, IgG2a, IgG2b, and
IgE, but not IgA (Fig. 2g).
To explore whether JunB is important for Treg cells to suppress
functions of speciﬁc T helper cells, we analyzed expression of
signature cytokines produced by distinct T helper cells (interferon
(IFN)-γ for Th1 cells, IL-4 and IL-13 for Th2 cells, and IL-17A for
Th17 cells). In spleen and lung, Foxp3CreJunbﬂ/ﬂ mice exhibited
more abundant cells expressing IFN-γ, IL-4, IL-13, and IL-17A
than did Junbﬂ/ﬂ mice (Fig. 2h). We also found that CD8+ T cells
with an activated phenotype (CD62LloCD44hi) or expression of
inﬂammatory cytokines (IFN-γ and IL-17A) were signiﬁcantly
increased in spleen and lung of Foxp3CreJunbﬂ/ﬂ mice, compared
with control mice (Supplementary Fig. 3d, e). Thus, loss of JunB
in Treg cells induces multi-organ autoimmune pathology
accompanied by activation of T helper cells, CD8+ T cells and
B cells, dysregulated leukocyte homeostasis in lymphoid tissues,
and enhanced production of immunoglobulins.
JunB regulates accumulation and function of Treg cells. We
next investigated whether autoimmune phenotypes of Foxp3Cre-
Junbﬂ/ﬂ mice are due to loss of Treg cells. First, we analyzed
abundances of Treg cells in various tissues. In colon of Foxp3-
CreJunbﬂ/ﬂ mice, CD4+Foxp3+ Treg cells were signiﬁcantly
decreased in both absolute numbers and proportions among
T cells (Fig. 3a), suggesting that a decrease of Treg cells might
partly explain the more severe inﬂammation observed in
the colon of Foxp3CreJunbﬂ/ﬂ mice. In contrast, abundance of
CD4+Foxp3+ Treg cells was normal in lung, liver, and skin, and
only slightly reduced in spleen in Foxp3CreJunbﬂ/ﬂ mice (Fig. 3a and
Supplementary Fig. 4a), suggesting that inﬂammation induced in
lung and spleen of the mice might not be due to loss of Treg cells.
To further explore why Treg-mediated self-tolerance cannot be
maintained in Foxp3CreJunbﬂ/ﬂ mice, we next analyzed abun-
dance of eTreg cells, as JunB was expressed in this population.
Foxp3CreJunbﬂ/ﬂ mice had normal or even increased numbers of
CD62Llo eTreg cells in the spleen and lung, but not in the colon,
compared with Foxp3CreJunb+/+ mice (Fig. 3b and supplemen-
tary Fig 4b, c). However, the mean ﬂuorescence intensity (MFI) of
CD44 was reduced in Junb-deﬁcient eTreg cells (Fig. 3b, c). We
also analyzed expression of Treg signature molecules and found
that there was no reduction in expression of CTLA4 and CD25 in
eTreg and cTreg cells of Foxp3CreJunbﬂ/ﬂ mice (Fig. 3d). GITR
(Glucocorticoid-Induced TNF receptor family-related protein)
was even upregulated in both eTreg and cTreg cells of
Foxp3CreJunbﬂ/ﬂ mice, probably owing to effects of inﬂammation
(Fig. 3d). Moreover, we analyzed expression of eTreg-related
molecules and found that in Junb-deﬁcient eTreg cells, ICOS
expression was severely diminished, but expression of TIGIT,
KLRG1, and ST2 (IL-33 receptor) was not affected (Fig. 3e).
These data indicate that JunB is not required for generation of
CD62Llo eTreg cells, but it promotes expression of CD44 and
ICOS in eTreg cells in diseased Foxp3CreJunbﬂ/ﬂ mice.
A subset of eTreg cells expresses transcription factors that have
lineage-deﬁning functions in T helper cells, such as T-bet,
GATA3, and RORγt19–24. These transcription factors likely
regulate migration and suppressive functions of eTreg cells in a
context-dependent manner. We analyzed expression of these
transcription factors in Treg cells of Foxp3CreJunbﬂ/ﬂ mice. There
was a signiﬁcant reduction of GATA3 and T-bet, but not RORγt,
in Treg cells in spleens of Foxp3CreJunbﬂ/ﬂ mice compared with
Foxp3CreJunb+/+ mice (Supplementary Fig. 4d).
To directly examine the functional importance of JunB in Treg
cell immune-suppressive activity, we performed an in vitro
suppression assay. Junb-deﬁcient Treg cells isolated from
Cd4CreJunbﬂ/ﬂ mice or Junb-sufﬁcient Treg cells isolated from
Junbﬂ/ﬂ mice were mixed with activated Tconv cells. Cell trace
violet (CTV) staining analysis showed that suppressive activity of
Junb-deﬁcient Treg cells was signiﬁcantly impaired (Fig. 3f).
Moreover, pre-activation of Treg cells with anti-CD3 antibody
enhanced suppression activity of Junb-sufﬁcient Treg cells, but
not Junb-deﬁcient Treg cells (Fig. 3f). Notably, upon stimulation
with anti-CD3 antibody, there was a signiﬁcant increase of
annexin-V+ cells in Junb-deﬁcient Treg cells, compared with
Junb-sufﬁcient Treg cells (Supplementary Fig. 5a). These data
suggest that JunB is required for survival of Treg cells upon
prolonged and/or strong TCR stimulation, which enhances
suppressive activity of Treg cells.
We also performed an in vivo suppression assay by co-
transferring Junb-deﬁcient Treg cells (CD4+CD25+) isolated
from Cd4CreJunbﬂ/ﬂ or Foxp3CreJunbﬂ/ﬂ mice with wild-type
naive CD4+ T cells into Rag1-deﬁcient mice. Unlike Junb-
sufﬁcient Treg cells, Junb-deﬁcient Treg cells could not suppress
weight loss and intestinal pathology in these mice (Fig. 3g and
supplementary Fig. 5b). Forty days after transfer, there was no
difference in the frequency of Junb-deﬁcient and -sufﬁcient Treg
cells in the spleen and lung (Supplementary Fig. 5c). However, in
the mesenteric lymph nodes and colon, frequency of Junb-
deﬁcient Treg cells was signiﬁcantly lower than that of Junb-
sufﬁcient Treg cells (Supplementary Fig. 5c). In summary, these
data suggest that JunB supports tissue-speciﬁc accumulation and
suppressive functions of Treg cells.
Fig. 2Mice deﬁcient for JunB in Treg cells develop autoimmune disease. a Body weight changes of male Foxp3CreJunbﬂ/ﬂ mice and control mice. Error bars
indicate s.e.m. (n= 11 for controls, n= 10 for Foxp3CreJunbﬂ/ﬂ mice). b Survival of male Foxp3CreJunbﬂ/ﬂ mice and control mice. Error bars indicate s.d. (n=
11 for controls, n= 22 for Foxp3CreJunbﬂ/ﬂ mice). c Total cell numbers in spleens, superﬁcial cervical lymph nodes (scLN), inguinal LN (iLN), and mesenteric
LN (mLN) of male Foxp3CreJunbﬂ/ﬂ mice and control mice (8–12-week-old). Error bars indicate s.d. (n= 5). *P < 0.05; N.S., not signiﬁcant (unpaired two-
tailed Student’s t test). d Hematoxylin and eosin staining of lung, colon, liver, and skin from 12-week-old male Foxp3CreJunbﬂ/ﬂ mice and control mice. Scale
bars, 50 μm (lung, colon, and liver) or 100 μm (skin). Bar graph shows histopathological inﬂammation scores. Error bars indicate s.d. (n= 5). *P < 0.05; N.
S., not signiﬁcant (unpaired two-tailed Student’s t test). e Flow cytometry analysis of CD62L and CD44 in CD4+Foxp3− Tconv cells isolated from various
tissues of male Foxp3CreJunbﬂ/ﬂ mice and Foxp3CreJunb+/+ mice (8–12-week-old). Representative ﬂow cytometry proﬁles show CD4+Foxp3− Tconv cells
isolated from the spleen. The graph shows percentages of CD62LloCD44hi activated cells among CD4+Foxp3− cells. Error bars indicate s.d. (n= 5 for
spleens, n= 3 for lymph nodes). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). fMass cytometry analysis of leukocytes isolated from
spleens of Foxp3CreJunbﬂ/ﬂ mice and Foxp3CreJunb+/+ mice (8–12-week-old). Mo: monocytes, Mϕ: macrophages, DC: dendritic cells. Size of each node
represents cell numbers. Expression levels of JunB is color-coded. g ELISA analysis of immunoglobulin isotypes in sera of 12-week-old male Foxp3CreJunbﬂ/ﬂ
mice and Foxp3CreJunb+/+ mice. Error bars indicate s.d. (n= 6 for Foxp3CreJunbﬂ/+ mice, n= 9 for Foxp3CreJunbﬂ/ﬂ mice). *P < 0.05; N.S., not signiﬁcant
(unpaired two-tailed Student’s t test). h Flow cytometry analysis of intracellular IL-17A, IFN-γ, IL-4, and IL-13 in CD4+Foxp3− cells isolated from spleens of
8–12-week-old male Foxp3CreJunbﬂ/ﬂ mice and Foxp3CreJunb+/+ mice. Error bars indicate s.d. (n= 5). *P < 0.05 (unpaired two-tailed Student’s t test). Data
represent two independent experiments
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JunB regulates expression of Treg effector genes. In
Foxp3CreJunbﬂ/ﬂ mice, Junb-deﬁcient Treg cell phenotypes may
be modulated by inﬂammation. To elucidate JunB function in
Treg cells under homeostatic (non-inﬂammatory) conditions, we
used Cd4CreJunbﬂ/ﬂ mice, which show no inﬂammatory signs,
probably owing to impaired activation of T helper cells42–44. We
ﬁrst analyzed Treg cell abundance in various lymphoid and non-
lymphoid tissues. Consistent with recent reports43, CD4+Foxp3+
Treg cells were diminished in all tissues examined in
Cd4CreJunbﬂ/ﬂ mice, with the greatest reduction in colon (Fig. 4a).
This implies that JunB is required for the accumulation of Treg
cells under non-inﬂammatory conditions.
We then analyzed eTreg cell abundance in Cd4CreJunbﬂ/ﬂ mice.
In spleens of Cd4CreJunbﬂ/ﬂ mice, the proportion of CD62Llo
eTreg cells among all Foxp3+ Treg cells was lower than in Junbﬂ/ﬂ
mice (Fig. 4b). As in diseased Foxp3CreJunbﬂ/ﬂ mice, MFIs of
CD44 expression in CD62Llo eTreg cells of Cd4CreJunbﬂ/ﬂ mice
were signiﬁcantly lower than in Junbﬂ/ﬂ mice (Fig. 4c). This
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suggests that JunB is involved in accumulation of eTreg cells
under homeostatic conditions.
We next assessed expression of signature molecules for Treg
cells and eTreg cells in Cd4CreJunbﬂ/ﬂ mice. Expression levels of
CTLA4, but not of CD25 and GITR, in eTreg cells were
signiﬁcantly lower in Cd4CreJunbﬂ/ﬂ mice than Junbﬂ/ﬂ mice
(Fig. 4d). In addition, there was a signiﬁcant reduction of
CD62Llo eTreg cells expressing ICOS, TIGIT, and KLRG1, but
not ST2, in spleens of Cd4CreJunbﬂ/ﬂ mice (Fig. 4e). Although we
detected decreases of GATA3 and T-bet in eTreg cells of
Foxp3CreJunbﬂ/ﬂ mice, those molecules were normally expressed
in eTreg cells of Cd4CreJunbﬂ/ﬂ mice (Supplementary Fig. 6a),
suggesting that JunB is involved in expression of GATA3 and T-
bet only under inﬂammatory conditions. Assay with antibodies
against neurophilin 1 (Nrp1) or Helios, which are markers for
Treg cells generated in the thymus (tTreg), revealed that ICOS
expression was signiﬁcantly decreased in Treg populations,
regardless of their expression of Nrp1 or Helios (Fig. 4f and
Supplementary Fig. 6b), suggesting that JunB promotes ICOS
expression in both tTreg cells and Treg cells induced in periphery
(pTreg). We also analyzed expression of eTreg signature
molecules in neonates, because Treg cells generated at that age
perform unique and essential functions to maintain self-
tolerance54. There was no difference in frequency of Treg cells
in the thymus between 1-week-old Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ
neonates (Supplementary Fig. 6c). However, expression of ICOS,
TIGIT, and KLRG1 in splenic Treg cells was severely decreased in
1-week-old Cd4CreJunbﬂ/ﬂ mice (Fig. 4g). Taken together, JunB is
needed for expression of a subset of effector molecules in eTreg
cells and for accumulation of eTreg cells under homeostatic
conditions.
JunB regulates eTreg homeostasis. We next examined whether
cell-intrinsic functions of JunB are required for generation and
homeostasis of Treg cells. To this end, we transferred bone
marrow (BM) cells from Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice
(CD45.2+), in combination with equal numbers of wild-type
(WT) BM cells (CD45.1+), into Rag1−/− mice, which generated
WT:Cd4CreJunbﬂ/ﬂ and WT:Junbﬂ/ﬂ BM chimeric mice, respec-
tively (Fig. 5a). These BM chimeric mice had comparable num-
bers of total Foxp3+ Treg cells in all tissues examined
(Supplementary Fig. 7). We then analyzed ratios of cells derived
from Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ BM cells (CD45.2+) relative to
those derived from WT BM cells (CD45.2−) among Treg popu-
lations. In the thymus, frequencies of Foxp3+ Treg cells derived
from Cd4CreJunbﬂ/ﬂ BM cells were equivalent to those derived
from Junbﬂ/ﬂ BM cells (Fig. 5b), indicating that cell-intrinsic
functions of JunB are not required for development of tTreg cells.
In contrast, in spleen and lung, Foxp3+ Treg cells derived from
Cd4CreJunbﬂ/ﬂ BM cells were signiﬁcantly under-represented,
compared with those derived from Junbﬂ/ﬂ BM cells (Fig. 5b).
Furthermore, the reduction of cells derived from Cd4CreJunbﬂ/ﬂ
BM was speciﬁc to the CD62Llo eTreg population, but not the
CD62LhiCD44lo cTreg population (Fig. 5c). We also conﬁrmed
impaired expression of ICOS and TIGIT in the remaining Junb-
deﬁcient CD62Llo eTreg cells (Fig. 5d, e), indicating that JunB
regulates expression of ICOS and TIGIT in a cell-intrinsic
manner.
The severe decrease of Junb-deﬁcient eTreg cells in WT:
Cd4CreJunbﬂ/ﬂ mice suggests that JunB is important for eTreg
homeostasis in a competitive setting. To further investigate this
phenotype, we analyzed the effect of JunB deﬁciency on
proliferation of Treg cells, using Ki67 staining. Proportions of
Ki67-expressing eTreg cells derived from Junbﬂ/ﬂCd4Cre BM cells
were severely decreased compared with those derived from Junbﬂ/
ﬂ BM cells (Fig. 5f). We also analyzed the effect of JunB deﬁciency
on Treg cell death, using Annexin-V staining. Frequencies of
Annexin-V-stained eTreg cells derived from Junbﬂ/ﬂCd4Cre BM
cells, but not Junbﬂ/ﬂ BM cells, were signiﬁcantly increased
(Fig. 5g). These data suggest that JunB intrinsically promotes
proliferation and survival of eTreg cells, which is important for
eTreg homeostasis in a competitive environment.
JunB is required for a transcriptional program for eTregs. To
understand JunB-dependent transcriptional regulation in Treg
cells, we performed RNA-sequence analysis of Junb-sufﬁcient and
Junb-deﬁcient Treg cells, isolated from Junbﬂ/ﬂ and Cd4CreJunbﬂ/ﬂ
mice, respectively. In total, 173 genes were downregulated and
137 genes were upregulated in Junb-deﬁcient Treg cells compared
with Junb-sufﬁcient Treg cells (p values < 0.05, log2 fold-changes
> 0.5 or < 0.5) (Fig. 6a). Gene ontology analysis of genes differ-
entially expressed in Junb-deﬁcient and -sufﬁcient Treg cells
showed enrichment for genes associated with metabolic processes
(Supplementary Fig. 8a). Furthermore, ingenuity pathway ana-
lysis (IPA) revealed that differentially expressed genes were
associated most signiﬁcantly with cell survival (Supplementary
Fig. 8b). IPA also identiﬁed CD3 and CD28 signaling pathways as
upstream regulators for genes affected by JunB deﬁciency (Sup-
plementary Fig. 8c).
To assess the function of JunB in a transcriptional program for
eTreg cells, we compared our data with previously identiﬁed
eTreg-related genes (genes that ICOS+ eTreg cells expressed
more highly than did ICOS− eTreg cells)18. Among 762 eTreg-
related genes, only 70, including Icos, Tigit, Fgl2, Ctla4, and Maf,
Fig. 3 JunB is required for accumulation and effector functions of Treg cells. a Flow cytometry analysis of Foxp3 in CD4+ T cells in spleens, lungs, and
colons of male Foxp3CreJunbﬂ/ﬂ and Foxp3CreJunb+/+ mice (8–12-week-old). Graphs show percentages and numbers of CD4+Foxp3+ Treg cells. Error bars
indicate s.d. (n= 5 for Foxp3CreJunb+/+ mice, n= 6 for Foxp3CreJunbﬂ/ﬂ mice). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). b, c
Flow cytometry analysis of CD44 and CD62L in CD4+Foxp3+ Treg cells isolated from spleens of male Foxp3CreJunbﬂ/ﬂ and Foxp3CreJunb+/+ mice (8–12-
week-old). Graph shows percentages of CD62hiCD44lo cTreg cells and CD62lo eTreg cells b, and MFIs of CD44 c. Error bars indicate s.d. (n= 7 for
Foxp3CreJunb+/+mice, n= 6 for Foxp3CreJunbﬂ/ﬂ mice). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). d, e Flow cytometry analysis of
CTLA4, CD25, and GITR d, and ICOS, TIGIT, KLRG1, and ST2 e in CD62hiCD44lo cTreg cells and CD62lo eTreg cells among CD4+Foxp3+ Treg cells
isolated from spleens of male Foxp3CreJunbﬂ/ﬂ and Foxp3CreJunb+/+ mice (8–12-week-old). Representative ﬂow cytometry proﬁles show CD62hiCD44lo
cTreg cells and CD62lo eTreg cells d, and CD62lo eTreg cells e. Graphs show MFIs of CTLA4, CD25, and GITR d, and percentages of cells expressing
indicated molecules e. Error bars indicate s.d. (n= 4). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). f CD4+CD25+ Treg cells were
isolated from Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. Treg cells freshly isolated or activated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2 for
3 days were used for in vitro suppression assay. CD4+CD25− Tconv cells (CD45.1) labeled with cell trace violet (CTV) were cultured with different
numbers of CD4+CD25+ Treg cells in the presence of anti-CD3-/anti-CD28-coated beads for 2 days, and CTV dilution was analyzed by ﬂow cytometry. g
In vivo suppression assay using CD4+CD25+ Treg cells isolated from Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. In all, 6–8-week-old sex-matched Rag1−/− mice
were injected with wild-type naive CD4+ T cells and CD4+CD25+ Treg cells. The graph shows body weight changes. Colonic histopathology was analyzed
on day 40 after injection. Error bars indicate s.e.m. (n= 5). Data represent two independent experiments
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were downregulated in Junb-deﬁcient Treg cells compared with
Junb-sufﬁcient Treg cells (Fig. 6a, b). We also compared our data
with previously identiﬁed genes regulated by BATF in Treg
cells24. Compared with JunB, many more eTreg-related genes
(256 genes out of 762) were downregulated by BATF deﬁciency
(Fig. 6b). Expression of only 34 eTreg-related genes, including
Icos and Fgl2, was promoted by both JunB and BATF (Fig. 6b). In
addition, expression of 36 eTreg-related genes, including Ctla4,
Tigit, and Maf was upregulated by JunB, but not BATF, whereas
expression of 222 eTreg-related genes, including Prdm1 and Nt5e
was promoted by BATF, but not JunB (Fig. 6b). In addition,
expression of Il1rl1 (encoding ST2) and chemokine receptors
Ccr2, Ccr9, and Ccr10 was upregulated by BATF, but not JunB
(Fig. 6b). These data indicate that JunB and BATF regulate shared
and unique target genes in the eTreg transcriptional program.
To elucidate mechanisms underlying JunB-dependent tran-
scriptional regulation, we conducted chromatin
immunoprecipitation-sequencing (ChIP-Seq) analysis using
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antibodies against JunB, as well as against BATF and IRF4. We
found that JunB-binding peaks overlapped signiﬁcantly with
BATF- and IRF4-binding peaks (Supplementary Fig. 9a). Among
peaks identiﬁed around gene-encoding regions (within 100 kb of
transcription start site), 35% of JunB peaks overlapped with
BATF and IRF4 (Supplementary Fig. 9b). Furthermore, among
peaks located around eTreg-related genes, higher numbers of
JunB peaks (47%) overlapped with BATF and IRF4 (Supplemen-
tary Fig. 9c). As in previously reported data for Th17 and CD8+
T cells36–40, de novo motif analysis identiﬁed AICE motifs in
overlapping ChIP-seq peaks for JunB, BATF, and IRF4
(Supplementary Fig. 9d).
We next investigated whether JunB is required for DNA-
binding of IRF4 by ChIP-seq analysis for IRF4 in Junb-sufﬁcient
and Junb-deﬁcient Treg cells. Global analysis of ChIP-seq peaks
revealed that levels of IRF4 DNA-binding were signiﬁcantly
decreased in 28% of ChIP-seq peaks that overlapped for IRF4 and
JunB (3190 out of 13,813 peaks, > 2× changes). De novo motif
analysis identiﬁed AP-1 and AICE motifs in overlapping ChIP-
seq peaks for JunB and IRF4, in which levels of IRF4-binding
were downregulated by JunB deﬁciency (supplementary Fig. 9e),
implying the importance of JunB for DNA-binding of IRF4 at a
subset of loci containing AICE motifs. We noted that at IRF4-
binding sites located between Icos and Ctla4, both of which are
upregulated by JunB and IRF4 in Treg cells, levels of some IRF4
peaks were reduced in Junb-deﬁcient Treg cells (Fig. 6c). To
conﬁrm this, we performed ChIP for IRF4 followed by PCR
analysis using primers to detect genomic regions in which
signiﬁcant decreases of DNA-binding of IRF4 by JunB deﬁciency
were shown in ChIP-seq data. JunB deﬁciency considerably
reduced IRF4 binding to sites located near Icos, Ctla4, Gzmb, and
Maf (Fig. 6d and Supplementary Fig. 9f, g). In contrast, at IRF4-
binding sites located near Prdm1 and Gata3, DNA binding of
IRF4 and BATF was not affected by JunB deﬁciency (Supple-
mentary Fig. 9h, i). We also conﬁrmed that JunB deﬁciency did
not affect expression levels of IRF4 and BATF in eTreg cells
(Supplementary Fig. 1e, f). These data suggest that JunB serves
key functions in expression of a subset of IRF4-dependent, eTreg-
related genes, probably by promoting DNA-binding of IRF4 at
sites associated with those genes.
Discussion
The TCR-dependent eTreg transcriptional program is indis-
pensable for Treg cells to maintain immune homeostasis6. Upon
TCR stimulation, IRF4 is induced and transcriptionally regulates
a variety of eTreg-related genes7. In addition, an AP-1 tran-
scription factor, BATF, which can interact with IRF4 to bind
AICE motifs, is also required for eTreg differentiation11,24,49.
However, it remains largely unclear how the IRF4-dependent
eTreg program is regulated by AP-1 transcription factors. In this
study, we show that the AP-1 transcription factor, JunB, as well as
BATF and IRF4, are highly expressed in ICOS+ eTreg cells. JunB
is critical for accumulation and suppressive functions of eTreg
cells, and Treg-speciﬁc ablation of JunB results in multi-organ
autoimmunity. Unlike IRF4, which is absolutely necessary for
CD62Llo eTreg generation, JunB regulates expression of a limited
set of key effector molecules, such as ICOS and CTLA4, pre-
sumably by regulating DNA-binding activity of IRF4 in a locus-
speciﬁc manner.
Our ChIP-seq data indicate that JunB colocalizes with BATF
and IRF4 at loci of large numbers of eTreg-related genes con-
taining AICE motifs. However, our RNA-seq data show that JunB
is needed for expression of only a small subset of eTreg-related
genes, such as Icos, Klrg1, Tigit, Ctla4, and Gzmb, in Treg cells.
Interestingly, although JunB and BATF regulate some shared
target genes, such as Icos and Klrg1, each regulates a unique set of
genes (e.g., Il1rl1 and Prdm1 for BATF, and Ctla4 and Tigit for
JunB). JunB likely promotes accumulation of IRF4 at loci of
selective eTreg-related genes, as loss of JunB severely decreases
DNA-binding of IRF4 at its target sites located near Icos, Ctla4,
Gzmb, and Maf. In addition, the necessity of JunB for IRF4-
dependent gene expression is likely context-dependent. For
example, expression of CTLA4 and TIGIT is decreased in eTreg
cells derived from Cd4CreJunbﬂ/ﬂ mice, but not from Foxp3Cre-
Junbﬂ/ﬂ mice, although expression of ICOS is decreased in eTreg
cells derived from both types of mice. In contrast, expression of
GATA3 and T-bet is diminished in eTreg cells derived from
Foxp3CreJunbﬂ/ﬂ mice, but not Cd4CreJunbﬂ/ﬂ mice. These results
suggest that the eTreg transcriptional program is differentially
regulated in homeostatic and inﬂammatory environments. It
remains unclear what determines the necessity of JunB for locus-
speciﬁc DNA-binding of IRF4. Future studies are needed to
identify differences in cis-regulatory elements or chromatin status
associated with the necessity of JunB.
JunB is not required for development of tTreg cells, as accu-
mulation of Junb-deﬁcient Treg cells is comparable to accumu-
lation of Junb-sufﬁcient Treg cells in the thymus of BM chimera
mice. However, JunB is required for accumulation of eTreg cells
in a context-dependent manner. Even though a sizeable fraction
of Treg cells differentiates into CD62Llo eTreg cells in Foxp3-
CreJunbﬂ/ﬂ mice, accumulation of Junb-deﬁcient eTreg cells, is
severely decreased in the presence of Junb-sufﬁcient Treg cells in
WT:Cd4CreJunbﬂ/ﬂ BM chimera mice. In WT:Cd4CreJunbﬂ/ﬂ BM
chimera mice, proliferation, and survival of Junb-deﬁcient eTreg
cells are signiﬁcantly decreased, suggesting that JunB is essential
for homeostasis of eTreg cells in a competitive setting under non-
inﬂammatory conditions. Given that ICOS promotes survival of
eTreg cells14, deﬁcient ICOS expression might partly explain
impaired ﬁtness in competitive environments for Junb-deﬁcient
eTreg cells.
Fig. 4 JunB regulates expression of eTreg-related molecules. a Flow cytometry analysis of CD4+Foxp3+ Treg cells in various tissues isolated from
Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. Graphs show percentages and numbers of CD4+Foxp3+ Treg cells. Error bars indicate s.d. (n= 4). *P < 0.05 (unpaired
two-tailed Student’s t test). b, c Flow cytometry analysis of CD44 and CD62L in CD4+Foxp3+ Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and Junbﬂ/
ﬂ mice (8–12-week-old). Graphs show percentages of CD62hiCD44lo cTreg and CD62lo eTreg cells b, and MFIs of CD44 c. Error bars indicate s.d. (n= 4).
*P < 0.05 (unpaired two-tailed Student’s t test). d, e Flow cytometry analysis of CTLA4, CD25, and GITR d, and ICOS, TIGIT, KLRG1, and ST2 e in
CD62hiCD44lo cTreg cells and CD62lo eTreg cells among CD4+Foxp3+ Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice (8–12-week-
old). Representative ﬂow cytometry proﬁles show CD62hiCD44lo cTreg cells and CD62lo eTreg cells d, and CD62lo eTreg cells e. Graphs show MFIs of
CTLA4, CD25, and GITR d, and percentages of cells expressing indicated molecules e. Error bars indicate s.d. (n= 4). *P < 0.05; N.S., not signiﬁcant
(unpaired two-tailed Student’s t test). f) Flow cytometry analysis of ICOS in Nrp1+ and Nrp1− Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ
mice (8–12-week-old). The graph shows percentages of ICOS-expressing cells among Nrp1+ and Nrp1− Treg cells. Error bars indicate s.d. (n= 4). *P < 0.05
(unpaired two-tailed Student’s t test). g Flow cytometry analysis of ICOS, TIGIT, and KLRG1 in CD4+Foxp3+ Treg cells isolated from spleens of 1-week-old
Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. Graphs show percentages of cells expressing indicated molecules among CD4+Foxp3+ Treg cells. Error bars indicate s.d.
(n= 3 for Junbﬂ/ﬂ, n= 7 for Cd4CreJunbﬂ/ﬂ). *P < 0.05 (unpaired two-tailed Student’s t test). Data represent two independent experiments
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JunB is also important for accumulation of eTreg cells in
peripheral tissues, particularly in the colon. As an adhesion
molecule CD44 is involved in T-cell migration to inﬂammatory
tissues55, reduced expression of CD44 in Junb-deﬁcient eTreg
cells may affect migration of eTreg cells. Our in vitro and in vivo
data indicate that JunB is also essential for TCR-dependent
suppressive functions of Treg cells by promoting survival of Treg
cells activated with strong and/or prolonged antigen signals.
Defects in suppressive function in Junb-deﬁcient Treg cells could
be also attributed to decreased expression of CTLA4, which is
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critical for Treg-dependent immune homeostasis17,56. In addi-
tion, our IPA analysis of genes affected by JunB deﬁciency sug-
gested that TCR signaling and cell survival might be regulated by
JunB. Thus, JunB-dependent modulation of the eTreg transcrip-
tional program is critical for accumulation and suppressive
functions of eTreg cells.
Foxp3CreJunbﬂ/ﬂ mice induce multi-organ autoimmunity, par-
ticularly in lung and colon, whereas Treg-speciﬁc Irf4-deﬁcient
(Foxp3CreIrf4ﬂ/ﬂ) mice develop autoimmune pathology in a
broader array of tissues, including lung, colon, skin, liver, and
pancreas34. Furthermore, although Th2 cells are preferentially
induced in Foxp3CreIrf4ﬂ/ﬂ mice34, not only Th2 cells, but also
Th1 and Th17 cells are aberrantly induced in Foxp3CreJunbﬂ/ﬂ
mice. In addition, Foxp3CreJunbﬂ/ﬂ and Foxp3CreIrf4ﬂ/ﬂ mice have
different sets of increased immunoglobulins. Although the dif-
ference in autoimmune pathology could be owing to distinct
animal housing environments and different levels of leaky Cre
expression in Tconv cells or CD8+ T cells, it might also reﬂect
functional differences between JunB and IRF4, discussed above.
eTreg cells express elevated levels of JunB, as well as BATF and
IRF4, but regulatory mechanisms for their expression are some-
what different. In Treg cells, the CD3 signal is not sufﬁcient to
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Fig. 6 JunB diversiﬁes targets for BATF and IRF4 in eTreg cells. a–c RNA-seq analysis of CD4+CD25+ Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and
Junbﬂ/ﬂ mice. a Volcano plot comparing gene expression of Treg cells isolated from Cd4CreJunbﬂ/ﬂ mice versus those from Junbﬂ/ﬂ mice. b Venn diagram of
genes upregulated by JunB (JunB-dependent genes) and BATF (BATF-dependent genes), and genes expressed in ICOS-expressing CD62Llo eTreg cells. c
ChIP-seq analysis of CD4+CD25+ Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. Cells were stimulated with anti-CD3 and anti-CD28
antibodies in the presence of IL-2 for 60 h and used for ChIP-Seq analysis with antibodies against JunB, BATF, and IRF4. The genomic region containing
Ctla4 and Icos genes was shown. The red box indicates a region located 28 kb downstream of transcription start site of Ctla4 (Ctla4 TSS+ 28 kb) in which
the level of IRF4-binding was signiﬁcantly decreased by JunB deﬁciency. Arrows indicate the direction of gene transcription. d ChIP-PCR analysis of
CD4+CD25+ Treg cells isolated from spleens of Cd4CreJunbﬂ/ﬂ and Junbﬂ/ﬂ mice. Cells were stimulated with anti-CD3 and anti-CD28 antibodies in the
presence of IL-2 for 72 h and used for ChIP with anti-IRF4 antibody. Immunoprecipitated DNA was analyzed by qPCR using primers to detect the IRF4-
binding site located in the Ctla4 TSS+ 28 kb region. Error bars indicate s.d. (n= 4). *P < 0.05 (unpaired two-tailed Student’s t test). Data represent two
independent experiments
Fig. 5 JunB is indispensable for eTreg homeostasis under competitive conditions. a Schematic of generation of bone marrow (BM) chimera mice. b–g
Lethally irradiated 6–8-week-old sex-matched Rag1−/− mice were transferred with BM cells from Cd4CreJunbﬂ/ﬂ (CD45.2) and Junbﬂ/ﬂ (CD45.2) mice, in
combination with equal numbers of WT BM cells from B6SJL (CD45.1), generating WT: Cd4CreJunbﬂ/ﬂ and WT: Junbﬂ/ﬂ BM chimera mice, respectively.
Two to three months later, cells were isolated from thymuses, spleens, and lymph nodes, and ratios of CD45.2+/CD45.2− in total CD4+Foxp3+ Treg cells
b, CD62LhiCD44lo cTreg cells and CD62Llo eTreg cells among CD4+Foxp3+ Treg cells c were determined by ﬂow cytometry analysis. Error bars indicate s.
d. (n= 6). *P < 0.05; N.S., not signiﬁcant (unpaired two-tailed Student’s t test). d–g Flow cytometry analysis of ICOS d, TIGIT e, Ki67 f, and Annexin-V g in
CD62LhiCD44lo cTreg cells and CD62Llo eTreg cells among CD4+Foxp3+ Treg cells isolated from spleens of WT: Cd4CreJunbﬂ/ﬂ and WT: Junbﬂ/ﬂ BM
chimera mice. Graphs show percentages of cells expressing indicated molecules or stained with Annexin-V. Error bars indicate s.d. (n= 4). *P < 0.05; N.S.,
not signiﬁcant (unpaired two-tailed Student’s t test). Data represent two independent experiments
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induce JunB and BATF, but CD28 and IL-2 signals promote
expression of JunB and BATF in an additive manner in the
presence of CD3 signaling. In contrast, IRF4 expression is
induced by CD3 signaling alone and is further augmented by
CD28 and IL-2 signals, but there is no additive effect between
CD28 and IL-2 signals. In addition, expression of BATF and IRF4
is transcriptionally upregulated, but JunB expression is regulated
post-transcriptionally in activated Treg cells. The mechanism of
post-transcriptional regulation of JunB expression may include
JNK-phosphorylation-mediated stabilization of JunB protein50.
Moreover, Treg cells express rather high levels of JunB, BATF,
and IRF4 in lung compared with spleen, suggesting that tissue-
speciﬁc signals modulate expression of JunB in peripheral tissues.
These observations suggest that JunB, by cooperating with BATF
and IRF4, integrates diverse signals to induce speciﬁc types of
eTreg cells. Furthermore, heterogeneity in expression of these
transcription factors can be generated during differentiation of
eTreg cells, which might contribute to functional heterogeneity of
eTreg cells.
In summary, we identify JunB as a key regulator of IRF4
activity in the eTreg transcriptional program. JunB serves non-
redundant functions to facilitate expression of a subset of IRF4
target genes in BATF-dependent and -independent fashions.
Thus, JunB could be a target for therapeutic manipulation of
speciﬁc functions of eTreg cells in immune and autoimmune
responses.
Methods
Mice. Junbﬂ/ﬂ mice were described previously42. Foxp3Cre (Foxp3YFP-Cre; stock#
016959), Cd4Cre (stock# 017336), Rag1−/− (stock# 002216), and B6SJL (stock#
002014) mice were obtained from the Jackson Laboratory. All mice were main-
tained on a C57BL/6 background under speciﬁc pathogen-free conditions. Sex-
matched, 6–12-week-old mice were used for experiments. All animal experimental
protocols were approved by the Animal Care and Use Committee at Okinawa
Institute of Science and Technology Graduate University.
Antibodies. For ﬂow cytometry analysis and FACS, the following antibodies were
used: anti-CD3 (17 A2, Biolegend, 1:400), anti-CD4 (GK1.5, Biolegend, 1:100 or
1:400), anti-CD8 (53–6.7, Biolegend, 1:400), anti-CD25 (PC61, Biolegend, 1:400),
anti-CD44 (IM7, Biolegend, 1:400), anti-CD62L (MEL-14, Biolegend, 1:400), anti-
CD19 (6D5, Biolegend, 1:400), anti-CD45R/B220 (RA3-6B2, Biolegend, 1:400),
anti-Fas (SA367H8, Biolegend, 1:400), anti-GL-7 (GL7, Biolegend, 1:400), anti-
CD138 (281–2, Biolegend, 1:400), anti-CTLA4 (UC10-4B9, Biolegend, 1:400), anti-
GITR (DTA-1, Biolegend, 1:400), anti-ICOS (7E.17G9, Biolegend, 1:100 or 1:400),
anti-TIGIT (1G9, Biolegend, 1:400), anti-KLRG1 (2F1/KLRG1, Biolegend, 1:400),
anti-ST2 (DIH9, Biolegend, 1:200), anti-IL-17A (TC11-18H10.1, Biolegend, 1:500),
anti-IFN-γ (XMG1.2, Biolegend, 1:100), anti-JunB (C-11, Santa Cruz Biotechnol-
ogy, 1:200), anti-IRF4 (IRF4.3E4, Biolegend,1:100), anti-BATF (D7C5, Cell Sig-
naling Technology, 1:400), anti-Foxp3 (150D, Biolegend, 1:100), anti-GATA3
(16E10A23, Biolegend,1:200), anti-RORγt (Q31-378, BD, 1:100), anti-T-bet (4B10,
Biolegend, 1:100), anti-Helios (22F6, Biolegend, 1:100), anti-CD45.1 (A20, Biole-
gend, 1:400), anti-CD45.2 (104, Biolegend, 1:400), anti-Ki-67 (16A8, Biolegend,
1:400), anti-goat IgG (Poly4053, Biolegend, 1:100 or 1:400), and anti-rabbit IgG
(Poly4064, Biolegend, 1:100 or 1:400). For ChIP analyses, anti-JunB (210, Santa
Cruz, 2 μg per ChIP), anti-BATF (WW8, Santa Cruz, 2 μg per ChIP), and anti-IRF4
(M-17, Santa Cruz, 2 μg per ChIP) were used.
Cell isolation. Cells were isolated from spleens, lymph nodes, and thymuses
by mashing them through cell strainers (BD; 352340). Cells were also isolated
from lungs and colonic lamina propria using a Lung Dissociation kit (Miltenyi;
130-095−927) and a Lamina Propria Dissociation kit (Miltenyi; 130-397-410),
respectively, according to the manufacturer’s instructions.
Flow cytometry. For analysis of cell surface molecules, cells were stained in
phosphate-buffered saline (PBS; Invitrogen; 21600) containing 2% fetal calf serum
(Biosera; FB-I061) for 30 min on ice. For analysis of intracellular molecules, cells
were stained with a Foxp3 Staining Buffer Set (eBioscience; 00-5253-00) according
to the manufacturer’s protocol. For analysis of intracellular cytokines, cells were re-
stimulated with phorbol 12-myristate 13-acetate (Sigma; P8139; 50 ng mL−1) and
ionomycin (Sigma; I0634; 500 ng mL−1) in the presence of brefeldin A (Biolegend;
420601; 5 μg mL−1), and then stained with a Foxp3 Staining Buffer Set. Before
antibody staining, cells were incubated with anti-Fc receptor-blocking antibody
(anti-CD16/CD32; Biolegend; 101320) and NIR-Zomibe (Biolegend; 423106). In
some experiments, dead cells were stained with Annexin-V (Biolegend, 1:400). The
gating strategy for ﬂow cytometry analysis and isotype control data are shown in
Supplementary Fig. 10.
Histological analysis. Mouse lung, colon, liver, and skin tissues were ﬁxed in 10%
formalin, processed, and stained with hematoxylin and eosin. Inﬂammatory scores
were determined by pathologists in the Biopathology Institute Co. Ltd., Japan.
Mass cytometry analysis. Cells isolated from mouse spleens were stained for
viability in PBS containing 50 μM cisplatin (Fludigm; 201198). Cells were then
incubated with anti-Fc receptor-blocking antibody (anti-CD16/CD32; Biolegend;
101320) for 10 min at room temperature, followed by staining with metal-
conjugated antibodies for cell surface molecules (Maxpar Mouse Spleen/Lymph
node Phenotyping Panel Kit; Fludigm; 201306) according to the manufacturer’s
protocol. Then, cells were ﬁxed and permeabilized using a Foxp3 staining buffer set
and subjected to staining with anti-Foxp3 antibody (Fludigm; FJK-16s-158Gd).
Cells were suspended in Maxpar water supplemented with 10% EQ Four Element
Calibration Beads (Fludigm; 201078) and analyzed on a Helios instrument (Flu-
digm) with Cytobank premium software.
Enzyme-linked immunosorbent assay. Serum was collected from 8–12-week-old
male Foxp3creJunbﬂ/ﬂ and control mice. Concentrations of IgE were determined
with a Mouse IgE ELISA MAX Standard kit (Biolegend, 432401), and concentra-
tions of IgG1, IgG2a, IgG2b, and IgA were determined as follows. Flat-bottom, 96-
well plates (Greiner, 655061) were coated with the following capture antibodies
overnight at 4oC: anti-mouse IgA (C10-1, BD, 1:500), anti-mouse IgG2a (R11-89,
BD, 1:500), anti-mouse IgG2b (R9-91, BD, 1:500), and anti-mouse IgG1 (A85-3,
BD, 1:500). Plates were washed and blocked with 0.05% Tween20 in PBS (PBST)
containing 5% bovine serum albumin (BSA, Wako, 018-15154) for 4 h at room
temperature. The following standard immunoglobulins were used for quantiﬁca-
tion: IgG1 (S1-68.1, BD), IgG2a (C76-47, BD), IgG2b (C48-4, BD), and IgA
(MOPC-320, BD). Samples were diluted with PBST containing 5% BSA (1:10,000
or 1:100,000 for IgA, 1:1,000,000 or 1:10,000,000 for IgG1, 1:120 or 1:1,200 for
IgG2a, 1:100,000 or 1:1,000,000 for IgG2b, 1:100, 1:1000, 1:10,000, or 1:100,000 for
IgE), added to plates, and incubated for 2 h at room temperature (for IgA and IgE)
or overnight at 4oC (for IgG1, IgG2a, and IgG2b). Plates were washed and incu-
bated with the following biotin-conjugated secondary antibodies for 1 h at room
temperature: anti-mouse IgA (C10-1, BD, 1:1000), anti-mouse IgG1 (A85-1, BD,
1:1000), anti-mouse IgG2a (R19-15, BD, 1:1000), and anti-mouse IgG2b (R12-3,
BD, 1:1000). Plates were then incubated with streptavidin conjugated with horse-
radish peroxidase (BD, 554066, 1:1000) for 30 min at room temperature. Plates
were then incubated with TMB (Sigma, T0440) for 10 min. The reaction was
stopped by 2 N sulfuric acid, and absorbance at 450 nm and 570 nm was read using
iMark plate reader (Bio-rad).
RT-qPCR analysis. Total RNA was isolated from FACS-sorted Treg cells using an
RNeasy Plus Mini Kit (Qiagen; 74136). Complementary DNA was synthesized
using a Revertra Ace qPCR Kit (Toyobo; FSQ-101) and subjected to qRT-PCR
analysis with Faststart SYBR master mix (4673484, Roche) and a Thermal Cycler
Dice Real Time system (Takara).
RNA-sequencing analysis. RNA-sequence libraries were prepared with NeoPrep
(Illumina) using TruSeq Stranded mRNA NeoPrep Kit (Illumina). Libraries were
then puriﬁed using Agencort AMPure XP (Beckman Coulter; A63880) at the ratio
of 3:2 to remove adapter-dimer, then quantiﬁed with droplet digital PCR (Bio-
Rad). Sequencing was performed on a HiSeq4000 (Illumina) with a HiSeq 3000/
4000 SBS Kit (300 Cycles, Illumina; FC-410–1003) and a HiSeq 3000/4000 PE
Cluster Kit (Illumina; PE-410-1001) to generate 150-nucleotide paired-end reads at
a read depth of at least 20 million reads per sample.
ChIP-seq and ChIP-PCR analyses. ChIP samples were prepared using a Sim-
pleChIP Plus Enzymatic Chromatin IP Kit (9005 S, Cell Signaling) as previously
described. Treg cells (2–8 × 105 per ChIP-seq or 1–4 × 105 per ChIP-PCR) were
activated with anti-CD3 antibody and anti-CD28 antibody in the presence of IL-2
for 60 h, cross-linked in culture medium containing 1% formaldehyde at room
temperature for 10 min, and glycine solution was added to stop the reaction. After
lysing cells, nuclei were isolated and treated with micrococcal nuclease (0.00313 μL
mL−1) for 20 min at 37°C, and the reaction was stopped by adding 0.05 M ethylene
glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA). Samples were
then sonicated to disrupt nuclear membranes and centrifuged to collect super-
natants containing chromatin. Chromatin solutions were incubated with 1 μg of
antibodies overnight at 4°C with rotation, and complexes of antibodies and
chromatin were collected with Protein G magnetic beads (Veritas; DB10003).
Beads were washed ﬁve times with low-salt wash solution and three times
with high-salt wash solution buffer (incubated for 5 min for each washing) at 4°C.
Chromatin was eluted, de-cross-linked following the manufacturer’s instructions,
puriﬁed by phenol/chloroform extraction, and used for ChIP-sequencing and
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ChIP-PCR analyses. Primers used for ChIP-PCR were listed in Supplementary
Table 1.
To prepare ChIP-seq libraries, immunoprecipitated DNA was blunt-ended and
ligated with adaptors using a KAPA Hyper Prep Kit (KAPA Biosystems; KK8500).
DNA was then cleaned up with an Agencort AMPure XP (Beckman Coulter;
A63880) at a 1.8 × DNA ratio, ampliﬁed by PCR, and puriﬁed using the AMPure
XP at a 1.2 × DNA ratio. Library DNA was size-selected using a 2% agarose gel
cassette of Blue Pippin (Sage Science) for a target size range 150–300 bp, quantiﬁed
with droplet digital PCR (Bio-Rad), and then sequenced on an Illumina HiSeq4000
to obtain 10 million uniquely aligned reads.
In vitro Treg suppression assay. Responder CD4+ T cells were isolated from B6.
SJL (CD45.1) mice and stained with CTV (Thermo Fisher Scientiﬁc; C34751).
CTV-stained responder cells (5 × 104 cells/well) were cultured alone or together
with CD4+CD25+ Treg cells, isolated freshly or pre-activated by anti-CD3/CD28
antibodies plus IL-2 for 2 days, in the presence of anti-CD3/CD28-coated Dyna-
beads (Invitrogen; 11456D; 1.25 × 104 beads/well). On day 3, cells were stained for
CD45.1, CD45.2, and CD4 and analyzed by ﬂow cytometry.
In vivo Treg suppression assay. Rag1−/− mice were intraperitoneally injected
with CD4+CD62LhiCD44loCD25- naive T cells (4 × 105 cells per mouse) isolated
from spleens and lymph nodes of wild-type C57BL/6 mice, together with or
without CD4+CD25hi Treg cells (2 × 105 cells per mouse) isolated from spleens and
lymph nodes of Cd4CreJunbﬂ/ﬂ or Junbﬂ/ﬂ mice. Mice were weighed to monitor
disease progress.
Mixed BM chimera mice. Rag1−/− recipient mice were lethally irradiated by X-ray
with a single dose of 6.5 Gy and 1 day later intravenously injected with a 1:1
mixture of BM cells from B6SJL (CD45.1) mice and Cd4CreJunbﬂ/ﬂ or Junbﬂ/ﬂ mice
(1 × 107 cells per mouse). Mice were given drinking water containing 1 mM Tri-
methoprim (Sigma-Aldrich; 46984) and 5 mM Sulfamethoxazole (Sigma-Aldrich;
31737) for 1 week before and after irradiation. Mice were maintained for at least
2 months after transplantation and used for analysis.
Statistical analysis. Unpaired two-tailed Student’s t tests were performed using
Prism software (GraphPad). P values < 0.05 were considered statistically signiﬁcant.
Data availability
The RNA-seq and ChIP-seq data have been deposited in the Gene Expression
Omnibus with the primary accession code GSE121295. CyTOF data were uploaded
in Cytobank (this data will be available from the authors upon request). All other
data supporting the ﬁndings of this study are available from the authors on request.
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